Amarin Corporation Third Quarter 2026 Results - AMARIN CORP PLC

Financial Performance:

• Achieved first profitable quarter in two years with net income of $245,000 (approx. $0.01/share), compared to a net loss of $7.7 million in Q3 2025.
• Total net revenue was $39.6 million, down from $49.7 million year-over-year; total product revenue was $36.9 million, while licensing and royalty revenue rose to $2.7 million from $1.1 million.
• U.S. product revenue declined to $28.5 million driven by lower net selling prices and generic competition, despite stable branded prescription volumes.
• Europe product revenue was $3.7 million (down from $4.1 million), while Rest of World revenue increased to $4.7 million (up from $3.6 million).
• Cost of goods sold decreased to $23.4 million from $27.5 million, yielding a sequential gross margin improvement of approximately 2.3 percentage points (excluding write-offs).
• Operating expenses fell 44% year-over-year (27% decline in SG&A, no restructuring costs vs. $9.4M previously); excluding restructuring, expenses were down 22%.
• Generated positive operating cash flow of $9 million for Q3; full-year operating cash flow for the first nine months totaled $22 million vs. a $9 million outflow in the prior period.
• Cash and investments ended at $324 million (up $21 million from year-end 2025) with zero debt on the balance sheet.
• Inventory levels decreased 31% from Q4 2024, reflecting disciplined working capital management.

Guidance and Future Outlook:

• Full-year outlook remains positive, with expectations for sustained positive operating cash flow.
• U.S. pricing expected to remain relatively consistent through the end of 2026 due to maintained exclusivity with key payers.
• Anticipates continued pricing pressure in 2027 as current U.S. exclusivity periods approach expiration, though exact terms for 2027 remain pending.
• U.S. volumes expected to remain stable through year-end.
• Strategic focus includes expanding global presence in 2027, with launches planned for Singapore and South Korea in early 2027.
• Capital deployment activities (e.g., share repurchases) will be determined following ongoing discussions with exclusive financial advisor Barclays.

Business Segments and Product Lines:

• U.S. IPE Market: Maintained 47% market share with competitive pricing and strong commercial discipline; managing business profitably despite generic competition.
• Europe (Vesepa): Commercialized via Recordati in 11 countries; launched in Poland in October on a private pay basis. In-market demand rose an estimated 68% in Q3 2026. Spain, UK, and Italy showing strong results.
• Rest of World: In-market demand rose 46% in Q3; total combined in-market demand for Vesepa grew 55% globally.
• Partnerships: Recordati partnership (59 countries) is driving momentum above historical European growth rates; partners preparing for Southeast Asian expansions.
• R&D/Regulatory: 28 publications released this year; icosapent ethyl (IPE) included in new European guidelines for cardiovascular and chronic kidney disease management.

Market and Competitive Landscape:

• IPE space described as highly competitive; Ameren retains U.S. leadership position.
• Generic competition is the primary driver of U.S. pricing pressure and revenue decline, though volume remains stable.
• European market expansion via Recordati offers access to 59 countries, including emerging markets, leveraging partner's cardiovascular heritage.
• Market sentiment positive on "in-market demand" growth metrics, which are viewed as a leading indicator for future partner supply purchases.

Risks and Challenges:

• Pricing Pressure: Ongoing U.S. pricing erosion due to generic competition and changes in customer mix.
• Revenue Timing Variance: International product revenue may not correlate perfectly quarter-to-quarter with in-market demand due to partner inventory levels and ordering patterns.
• Exclusivity Exposure: U.S. exclusivity agreements are set to expire by end of 2026, introducing uncertainty for 2027 pricing and market dynamics.
• Clinical Uncertainty: EMT2 trial failed its primary endpoint (progression-free survival), requiring further investigation before commercial potential in oncology is realized.
• Forward-Looking Statements: Management warns that actual results may differ materially from expectations due to various risks and uncertainties.

Management Commentary and Tone:

• Tone is described as confident and optimistic, emphasizing a "position of strength" post-restructuring.
• Management highlights "tangible, operational, and financial benefits" from the business transformation, including a lower cost base and debt-free status.
• CEO Aaron Berg stressed accountability to shareholders and the value of the Recordati partnership in unlocking untapped potential.
• CFO Pete Fishman noted significant progress in reducing the go-forward cost structure and maintaining disciplined working capital management.
• CEO referenced continued collaboration with Barclays regarding potential capital deployment (e.g., share repurchases).

Analyst Questions and Answers:

• J.P. Morgan (Jessica Fye): Asked about the discrepancy between stable script volumes and declining U.S. revenue.
  • Response: Volume was flat; revenue decline was entirely due to pricing pressure. Pricing expected to stay consistent through 2026 but face continued pressure in 2027.
• Goldman Sachs (Paul Choi): Inquired about European reimbursement progress and criteria for new therapeutic applications.
  • Response: Recordati is actively pursuing reimbursement beyond major Western markets, including new launches (Poland) and efforts in France. Regarding new indications (e.g., cancer), management will prioritize commercial viability, unmet need, and data protection, potentially seeking partnerships for co-funding future development.

Other Key Points:

• EMT2 Trial Results: Investigator-initiated Phase 3 trial in colorectal cancer patients showed a statistically significant 32% lower hazard of death in overall survival, despite missing the primary endpoint of progression-free survival. Data presented at ESMO Congress.
• Mechanistic Research: Studies confirm EPA incorporation into colorectal tissue and suggest broad biological effects (inflammation, anti-neoplastic activity) warranting further study.
• Reduction of Debt: The company has achieved a zero-debt balance sheet with $324 million in cash.
• Restructuring Benefits: Completed restructuring has eliminated one-time costs and established a lower permanent cost base.
• Upcoming Events: 2026 American Heart Association scientific sessions are expected to present new data on lipoprotein A.